Fernando Salvador
Research Subjects
Fernando Salvador has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Tomás Pascual
SOLTI Breast Cancer Research Group, Barcelona, Spain; Medical Oncology Department, Hospital Clinic Barcelona, Barcelona, Spain
34 shared publications - Juan Manuel Ferrero-Cafiero
SOLTI Cancer Research Group, Barcelona, Spain
33 shared publications - Xavier Gonzalez Farre
Medical Oncology, Hospital Universitari General de Catalunya, Instituto Oncológico Dr Rosell, Pangaea Oncology, Sant Cugat del Vallès, Spain
25 shared publications - Guillermo Villacampa
Statistical Unit, Vall d’Hebron Institute of Oncology, Barcelona, Spain
24 shared publications - Eva Ciruelos
Medical Oncology Department, Hospital 12 de Octubre, Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (Imas12), Madrid, Spain; SOLTI Cancer Research Group, Barcelona, Spain
23 shared publications - Mafalda Oliveira
Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Medical Oncology Department, Vall d'Hebron Hospital, Barcelona, Spain
23 shared publications
Latest Publications
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 9-17 from Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
Tables S9-S17 showing mutivariate and bivariate analysis for ORR, CBR, PFS and OS
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 9-17 from Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
Tables S9-S17 showing mutivariate and bivariate analysis for ORR, CBR, PFS and OS
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
Patient-level raw gene expression data of FFPE tumor samples and best overall response rate
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
Patient-level raw gene expression data of FFPE tumor samples and best overall response rate
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Data from Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
Purpose:Hormone receptor–positive (HR+), HER2-negative (HER2−) metastatic breast cancer (mBC) is biologically distinct from early-stage disease, with a higher prevalence of genomically defined nonluminal subtypes, particularly the HER2-enriched (HER2-E) and basal-like subtypes. These tumors are highly proliferative, less dependent on hormone signaling, and associated with poor outcomes and early resistance to endocrine therapy and CDK4/6 inhibition (CDK4/6i). This biological shift highlights the need for biomarker-driven strategies in the CDK4/6i-resistant setting.Patients and Methods:The SOLTI-1716 TATEN trial (NCT04251169) is a phase II, single-arm study evaluating the combination of pembrolizumab and paclitaxel in patients with HR+/HER2− mBC classified as HER2-E or basal-like by PAM50 following progression on CDK4/6i. A total of 126 patients were screened using the PAM50 genomic assay; 20 with HER2-E or basal-like subtypes were enrolled and received pembrolizumab (200 mg every 3 weeks) and paclitaxel (80 mg/m2 weekly).Results:The primary endpoint, overall response rate (ORR), was 61.1% [95% confidence interval (CI), 35.7–82.7], and the clinical benefit rate was 94.4% (95% CI, 72.7–99.9). The median progression-free survival was 8.1 months (95% CI, 5.9–10.4), and the median overall survival was 26 months [95% CI, 18−not reached (NR)]. Three patients achieved durable responses lasting ≥24 months. Gene expression analyses revealed that high expression of proliferation- and immune-related genes predicted improved ORR and survival, whereas luminal-related gene expression was associated with lower clinical benefit.Conclusions:These results suggest that chemo-immunotherapy may be an effective strategy in genomically defined nonluminal subtypes of HR+/HER2− mBC following CDK4/6i resistance and highlight the value of molecular subtyping to guide post–endocrine treatment decisions.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
Purpose:Hormone receptor–positive (HR+), HER2-negative (HER2−) metastatic breast cancer (mBC) is biologically distinct from early-stage disease, with a higher prevalence of genomically defined nonluminal subtypes, particularly the HER2-enriched (HER2-E) and basal-like subtypes. These tumors are highly proliferative, less dependent on hormone signaling, and associated with poor outcomes and early resistance to endocrine therapy and CDK4/6 inhibition (CDK4/6i). This biological shift highlights the need for biomarker-driven strategies in the CDK4/6i-resistant setting.Patients and Methods:The SOLTI-1716 TATEN trial (NCT04251169) is a phase II, single-arm study evaluating the combination of pembrolizumab and paclitaxel in patients with HR+/HER2− mBC classified as HER2-E or basal-like by PAM50 following progression on CDK4/6i. A total of 126 patients were screened using the PAM50 genomic assay; 20 with HER2-E or basal-like subtypes were enrolled and received pembrolizumab (200 mg every 3 weeks) and paclitaxel (80 mg/m2 weekly).Results:The primary endpoint, overall response rate (ORR), was 61.1% [95% confidence interval (CI), 35.7–82.7], and the clinical benefit rate was 94.4% (95% CI, 72.7–99.9). The median progression-free survival was 8.1 months (95% CI, 5.9–10.4), and the median overall survival was 26 months [95% CI, 18−not reached (NR)]. Three patients achieved durable responses lasting ≥24 months. Gene expression analyses revealed that high expression of proliferation- and immune-related genes predicted improved ORR and survival, whereas luminal-related gene expression was associated with lower clinical benefit.Conclusions:These results suggest that chemo-immunotherapy may be an effective strategy in genomically defined nonluminal subtypes of HR+/HER2− mBC following CDK4/6i resistance and highlight the value of molecular subtyping to guide post–endocrine treatment decisions.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 5-8 from Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
Tables S5-8 showing results from univariate analysis for ORR, CBR, PFS and OS
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 5-8 from Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
Tables S5-8 showing results from univariate analysis for ORR, CBR, PFS and OS
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
Supplementary Table S2 | Criteria for defining DLT. AE, adverse events; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CTCAE, Common Terminology Criteria for Adverse Events; DLT, dose-limiting toxicities; GI, gastrointestinal; LLN, lower limit of normal; SOC, standard of care; ULN, upper limit of normal.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
Supplementary Table S2 | Criteria for defining DLT. AE, adverse events; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CTCAE, Common Terminology Criteria for Adverse Events; DLT, dose-limiting toxicities; GI, gastrointestinal; LLN, lower limit of normal; SOC, standard of care; ULN, upper limit of normal.